Literature DB >> 16417990

In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus.

Natsuo Yamamoto1, Jiro Fujita, Takashi Shinzato, Futoshi Higa, Masao Tateyama, Masato Tohyama, Isamu Nakasone, Nobuhisa Yamane.   

Abstract

The in vitro activities of sitafloxacin and seven other fluoroquinolones a (ciprofloxacin, tosufloxacin, sparfloxacin, levofloxacin, T-3811ME, moxifloxacin and trovafloxacin) were examined by the microdilution method against 79 clinically isolated 'Streptococcus milleri' group (SMG) microorganisms. No statistically significant differences were found between the minimum inhibitory concentrations (MIC(50) and MIC(90)) against Streptococcus anginosus and Streptococcus constellatus. Sitafloxacin was the most active agent of the eight fluoroquinolones tested against SMG, with a MIC(90) of 0.06 microg/mL, which was 8 times more active than ciprofloxacin and 16 times more active than levofloxacin. Although none of the SMG strains showed high resistance to any of the fluoroquinolones tested, three agents (trovafloxacin, sitafloxacin and T-3811ME) had low MICs against 23 SMG strains against which levofloxacin had a MIC> 1 microg/mL. In conclusion, several fluoroquinolones have low MICs against SMG, but sitafloxacin has the lowest.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417990     DOI: 10.1016/j.ijantimicag.2005.10.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Evaluation of Biliary Bacterial Resistance in Patients with Frequent Biliary Instrumentation, One Size Does Not Fit All.

Authors:  Maen Masadeh; Subhash Chandra; Daniel Livorsi; Frederick Johlin; William Silverman
Journal:  Dig Dis Sci       Date:  2018-08-28       Impact factor: 3.199

Review 2.  Sitafloxacin: in bacterial infections.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

3.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

4.  Clinical and microbiologic characteristics of pleuro-pulmonary infection due to Streptococcus intermedius.

Authors:  F Cobo; A Sampedro; J Rodríguez-Granger; L Aliaga-Martínez; J M Navarro-Marí
Journal:  Rev Esp Quimioter       Date:  2018-03-22       Impact factor: 1.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.